Several major hedge funds are recruiting doctors, scientists, and pharmaceutical analysts to gain insights into pharmaceutical companies amidst stock price volatility. According to sources, hedge funds including Balyasny, DE Shaw, Point72, Schonfeld, Qube, and Squarepoint, managing over $200 billion in assets, are hiring these experts globally.
The goal is to understand growth prospects, such as which early-stage drug trials may receive regulatory approval. This trend has intensified as borrowing costs in Western economies decline, prompting expanded pharmaceutical R&D. A notable instance of stock fluctuation was AbbVie's 12% drop following a failed schizophrenia drug trial, while competitor Bristol Myers Squibb rose by 10%.
Hedge funds are increasingly interested in the healthcare sector, driven by technological advancements and AI in pharmaceuticals.
